
Electronics-Free Soft Robot Runs 4.72 m/s
The 3D-printed, air-powered machine is a lab result in Science Robotics, not a product, with untethered operation still to be built.

The 3D-printed, air-powered machine is a lab result in Science Robotics, not a product, with untethered operation still to be built.
For readers in America's Finest City, We are The Frontier covers biotechnology, defense and naval systems, telecommunications and the clean energy research that has made San Diego one of the most scientifically productive technology markets in the country. Reporting reaches neighborhoods across the city and the surrounding area.
The protest links campus AI licenses to data center opposition and military contracts, raising questions for universities that rely on commercial models.
Live Poll
Do you believe investors should prioritize funding for local creative industries to support economic growth?
Startups
The firm finishes its $15 million strategy, citing a $2 billion funding need within the creative-economy pipeline.

Live Poll
Should your city spend more on planting trees to cool neighborhoods?
The planting supports the city's goal of 100,000 new trees by 2035, a target that current pace of nearly 8,000 trees over two years has yet to match.

San Diego reporting takes in biotechnology and pharmaceutical development across San Diego County, naval defense and systems engineering, telecommunications and wireless technology, clean energy research, and the startups and employers hiring locally. From La Jolla and Pacific Beach to Ocean Beach, Hillcrest and North Park, coverage runs through the city and extends into Orange County, Riverside County and Imperial County where a project crosses the line. San Diego Unified School District workforce and technical programs connect to the biotech and engineering hiring story that runs through the metro. The Padres, San Diego Wave FC and San Diego FC mark the sports anchors of a city whose biotechnology sector — anchored by research institutions in the Torrey Pines corridor — generates a volume of clinical and commercialization coverage that rivals much larger markets.